OncoGenex to Webcast Discussion of Fourth Quarter 2011 Financial Results on Thursday, March 8, 2012

^{Published on 2012-02-28 13:10:51 - Market Wire}
 

OncoGenex to Webcast Discussion of Fourth Quarter 2011 Financial Results on Thursday, March 8, 2012

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about OGXI
Follow the latest news about TEVA

BOTHELL, WA and VANCOUVER, British Columbia, Feb. 28, 2012 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: [ OGXI ]) announced today that the Company's fourth quarter 2011 financial results will be released on Thursday, March 8, 2012, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide an update on the business.

To access the webcast, log on to the Investor Relations page of the OncoGenex website at [ www.oncogenex.com ]. Alternatively, you may access the live conference call by dialing (877) 606-1416 (U.S. &Canada) or (707) 287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived on [ www.oncogenex.com ] for 90 days.

About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at [ www.OncoGenex.com ].

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial initiation. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk that subsequent studies may not confirm earlier trial results, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company's Quarterly Report on Form 10-Q for third quarter ended September 30, 2011. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

SOURCE OncoGenex Pharmaceuticals, Inc.